01.12.26 -- Survey: SUS Insufficient For 40% Of Biopharma

Discover how to gain precise control over one of the most common and critical forms of protein modification for therapeutic benefit and stability.

Take a deeper look into innovative solutions for researchers facing challenges throughout the development of novel cell and gene therapeutics.

Demand for EVs is rising due to their therapeutic promise. Explore two scalable platforms that address production challenges to support EVs' expanding clinical and commercial applications.

Gain valuable insights to guide informed decisions in virus filtration, aligning with both the PDA TR-41 (2022) and ICH-Q5A guidelines.

A study demonstrates how a low-shear, closed-system centrifuge achieved over 90% MSC recovery and minimized viability loss, supporting scalable cell therapy manufacturing.

Optimize cell culture for solid tumor research. Replacing traditional serum can significantly enhance CAR-T cytotoxicity, improve consistency, and streamline the path to GMP-ready workflows.

Find out how a chemically defined viral feed can boost AAV titers by up to 8-fold, supporting multiple serotypes and both suspension and adherent HEK293 cell lines, simplifying scalability.

To ensure speed and stability in the manufacture of your complex biologic — mAbs, antibodies, fusion proteins, and/or antibody drug conjugates — prioritize a high-performance CLD workflow.

Learn about a platform that consists of several technologies allowing for the cultivation and monitoring of CHO cells in cell line development.